retardation. Am. J. Med. Genet., 93, 294-298
(2000).
PRECISIO is a registered trademark of Sigma-Aldrich
Biotechnology LP and Sigma-Aldrich Co.
TD,MAM 03/11-1
Sigma brand products are sold through
mental
retardation. Am. J. Med. Genet., 93, 294-298
(2000).
Precisio is a trademark of Sigma-Aldrich
Biotechnology LP and Sigma-Aldrich Co.
BKR,MAM 03/10-1
Sigma brand products are sold through
retardation. Am. J. Med. Genet., 93, 294-298
(2000).
Precisio is a registered trademark of Sigma-Aldrich
Biotechnology LP and Sigma-Aldrich Co.
BKR,MAM 08/10-1
Sigma brand products are sold
mental
retardation. Am. J. Med. Genet., 93, 294-298
(2000).
Precisio is a trademark of Sigma-Aldrich
Biotechnology LP and Sigma-Aldrich Co.
BKR,MAM 06/10-1
Sigma brand products are sold through
PAK3,
R67C, causes X-linked nonspecific mental
retardation. Am. J. Med. Genet., 93, 294-298
(2000).
BKR,MAM 02/09-1
Sigma brand products are sold through Sigma-Aldrich, Inc.
Sigma-Aldrich, Inc.
15, 290-298 (1996).
3. Paavonen, K., et al., Novel human vascular
endothelial growth factor genes VEGF-B and
VEGF-C localize to chromosomes 11q13 and 4q34,
respectively. Circulation, 93, 1079-1082
(1997).
7. Afework, M. and Burnstock, G., Cell Tissue Res.,
298, 449 (1999).
8. Hansen, M.A. et al., J. Auton. Nerv. Syst., 78, 1
(1999).
9. Kanijan, R. et al., J. Comp. Neurol., 407, 11 (1999
(1997).
8. Afework, M. and Burnstock, G., Cell Tissue Res.,
298, 449 (1999).
9. Hansen, M.A. et al., J. Auton. Nerv. Syst., 78, 1
(1999).
10. Kanijan, R. et al., J. Comp. Neurol., 407, 11 (1999
1997).
6. Afework, M. and Burnstock, G., Cell Tissue Res.,
298, 449 (1999).
7. Hansen, M.A. et al., J. Auton. Nerv. Syst., 78, 1
(1999).
8. Kanijan, R. et al., J. Comp. Neurol.
196-197 (1995).
7. Knowles, R.G. and Moncada, S. Nitric oxide
synthases in mammals. Biochem. J. 298, 249−258
(1994).
8. Hevel, J. M., White, K. A., and Marletta, M.A.
Purification of the inducible
E. et al., Biochem., 4, 2219, (1965).
6. Shaw, E. and Glover, G., Arch. Biochem. Biophys., 139, 298, (1970).
7. Hara, S. et al., Exp. Cell Res., 223, 372, (1996).
8. Tsilikounas, E. et al., Biochem
Nature, 312, 763 (1985).
Furley, A. J., et al., Cell, 46, 75 (1986).
Garson, J. A., et al., Nature, 298, 375 (1982).
Glazer, N., et al., J. Biophys. Soc., 43, 383 (1982).
Gold, D., et al., Nature, 321
favorable from
unfavorable prognostic markers in breast cancer:
the role of E-cadherin. Cancer Res., 60, 298–304
(2000).
7. Hunt, N.C.A. et al., Loss of E-cadherin expression
associated with lymph node metastases
activation. Biol. Cell, 93, 53-62 (2001).
4. Johnson, G.L., and Lapadat, R., Mitogen-
activated protein kinase pathways mediated by
ERK, JNK, and p38 protein kinases. Science,
298, 1911-1912 (2002).